211 related articles for article (PubMed ID: 31796878)
1. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.
Niedermaier B; Sak A; Zernickel E; Xu S; Groneberg M; Stuschke M
Sci Rep; 2019 Dec; 9(1):18207. PubMed ID: 31796878
[TBL] [Abstract][Full Text] [Related]
2. Targeting of BRM Sensitizes
Zernickel E; Sak A; Riaz A; Klein D; Groneberg M; Stuschke M
Mol Cancer Ther; 2019 Mar; 18(3):656-666. PubMed ID: 30478150
[TBL] [Abstract][Full Text] [Related]
3. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
4. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
[TBL] [Abstract][Full Text] [Related]
5. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
6. ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Helming KC; Wang X; Wilson BG; Vazquez F; Haswell JR; Manchester HE; Kim Y; Kryukov GV; Ghandi M; Aguirre AJ; Jagani Z; Wang Z; Garraway LA; Hahn WC; Roberts CW
Nat Med; 2014 Mar; 20(3):251-4. PubMed ID: 24562383
[TBL] [Abstract][Full Text] [Related]
7. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
8. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
Park Y; Chui MH; Suryo Rahmanto Y; Yu ZC; Shamanna RA; Bellani MA; Gaillard S; Ayhan A; Viswanathan A; Seidman MM; Franco S; Leung AKL; Bohr VA; Shih IM; Wang TL
Clin Cancer Res; 2019 Sep; 25(18):5584-5594. PubMed ID: 31196855
[TBL] [Abstract][Full Text] [Related]
9. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
[TBL] [Abstract][Full Text] [Related]
10. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice.
Mathur R; Alver BH; San Roman AK; Wilson BG; Wang X; Agoston AT; Park PJ; Shivdasani RA; Roberts CW
Nat Genet; 2017 Feb; 49(2):296-302. PubMed ID: 27941798
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation.
Stubbs FE; Flynn BP; Rivers CA; Birnie MT; Herman A; Swinstead EE; Baek S; Fang H; Temple J; Carroll JS; Hager GL; Lightman SL; Conway-Campbell BL
Oncogene; 2022 Dec; 41(50):5347-5360. PubMed ID: 36344675
[TBL] [Abstract][Full Text] [Related]
12. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
[TBL] [Abstract][Full Text] [Related]
13. Targeting BRG1 chromatin remodeler via its bromodomain for enhanced tumor cell radiosensitivity in vitro and in vivo.
Kwon SJ; Lee SK; Na J; Lee SA; Lee HS; Park JH; Chung JK; Youn H; Kwon J
Mol Cancer Ther; 2015 Feb; 14(2):597-607. PubMed ID: 25504753
[TBL] [Abstract][Full Text] [Related]
14. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
15. Improved chemoradiation treatment using trifluridine in human colorectal cancer cells in vitro.
Matsuoka K; Kobunai T; Nukatsuka M; Takechi T
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):249-255. PubMed ID: 29024630
[TBL] [Abstract][Full Text] [Related]
16. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
17. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.
Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138
[TBL] [Abstract][Full Text] [Related]
18. ARID1A loss in cancer: Towards a mechanistic understanding.
Mathur R
Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
[TBL] [Abstract][Full Text] [Related]
19. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
20. IGF-1R depletion sensitizes colon cancer cell lines to radiotherapy.
Zong R; Chen X; Feng J; Xu S
Cancer Biomark; 2021; 32(2):199-206. PubMed ID: 34092618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
